Trends In Biopharmaceutical Clinical Trials After Medicare Drug Price Negotiation
Health Affairs · 2026
DOI: 10.1377/hlthaff.2025.00720 ↗Kurz gefasst
Fachartikel in der Zeitschrift Health Affairs, 2026. Verfasst von So-Yeon Kang und 2 weiteren Autor:innen. Beteiligte Einrichtung: So-Yeon Kang, Georgetown University, Washington, D.C. Hauptthemen laut MEDLINE: Drug Costs, Clinical Trials as Topic, Medicare, Negotiating. Die Arbeit nennt 12 Literaturangaben.
Abstract (Originalsprache)
The Inflation Reduction Act of 2022 authorized Medicare to negotiate prices for selected drugs, with implications for innovation. Using ClinicalTrials.gov data on biopharmaceutical trials initiated during 2015-24, we found that overall trial activity remained stable, returning to prepandemic levels, but manufacturers with drugs subject to negotiation initiated fewer trials, particularly in certain cancers.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- So-Yeon Kang, Georgetown University, Washington, D.C.
- Mingqian Liu, Georgetown University.
- Yunan Ji (yunan.ji@georgetown.edu), Georgetown University.
Zitieren
APA
Kang, S. Y., Liu, M., & Ji, Y. (2026). Trends In Biopharmaceutical Clinical Trials After Medicare Drug Price Negotiation. Health Affairs. https://doi.org/10.1377/hlthaff.2025.00720
Vancouver
Kang SY, Liu M, Ji Y. Trends In Biopharmaceutical Clinical Trials After Medicare Drug Price Negotiation. Health Affairs. 2026. doi:10.1377/hlthaff.2025.00720
BibTeX
@article{Kang2026,
author = {Kang, So-Yeon and Liu, Mingqian and Ji, Yunan},
title = {Trends In Biopharmaceutical Clinical Trials After Medicare Drug Price Negotiation},
journal = {Health Affairs},
year = {2026},
doi = {10.1377/hlthaff.2025.00720}
}
EUVIMED